Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning,...

Full description

Bibliographic Details
Main Author:	Brent L. Rollins
Format:	Article
Language:	English
Published:	Kerman University of Medical Sciences 2016-04-01
Series:	International Journal of Health Policy and Management
Subjects:	Food and Drug Administration (FDA) Direct-to-Consumer Advertising (DTCA) Notice of Violations (NOV) Office of Prescription Drug Promotion (OPDP) Fair Balance
Online Access:	http://www.ijhpm.com/pdf_3159_c3eba2a1569361b654b9856b57228c65.html

id	doaj-49f30a9a19744c4a8ef17286cbcef813
record_format	Article
spelling	doaj-49f30a9a19744c4a8ef17286cbcef8132020-11-24T23:06:25ZengKerman University of Medical SciencesInternational Journal of Health Policy and Management2322-59392322-59392016-04-015428728810.15171/ijhpm.2016.17Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”Brent L. Rollins0School of Pharmacy, Philadelphia College of Osteopathic Medicine (PCOM), Suwanee, GA, USAThe above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?http://www.ijhpm.com/pdf_3159_c3eba2a1569361b654b9856b57228c65.htmlFood and Drug Administration (FDA)Direct-to-Consumer Advertising (DTCA)Notice of Violations (NOV)Office of Prescription Drug Promotion (OPDP)Fair Balance
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Brent L. Rollins
spellingShingle	Brent L. Rollins Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters” International Journal of Health Policy and Management Food and Drug Administration (FDA) Direct-to-Consumer Advertising (DTCA) Notice of Violations (NOV) Office of Prescription Drug Promotion (OPDP) Fair Balance
author_facet	Brent L. Rollins
author_sort	Brent L. Rollins
title	Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
title_short	Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
title_full	Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
title_fullStr	Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
title_full_unstemmed	Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
title_sort	still the great debate – “fair balance” in direct-to-consumer prescription drug advertising; comment on “trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of fda warning letters”
publisher	Kerman University of Medical Sciences
series	International Journal of Health Policy and Management
issn	2322-5939 2322-5939
publishDate	2016-04-01
description	The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?
topic	Food and Drug Administration (FDA) Direct-to-Consumer Advertising (DTCA) Notice of Violations (NOV) Office of Prescription Drug Promotion (OPDP) Fair Balance
url	http://www.ijhpm.com/pdf_3159_c3eba2a1569361b654b9856b57228c65.html
work_keys_str_mv	AT brentlrollins stillthegreatdebatefairbalanceindirecttoconsumerprescriptiondrugadvertisingcommentontroublespotsinonlinedirecttoconsumerprescriptiondrugpromotionacontentanalysisoffdawarningletters
_version_	1725623033177047040

Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

Similar Items